demic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-
44. López-Macías,C.etal.Safetyandimmunogenicityofavirus-likeparticlepan-
Influenza-Vaccinology-Report.pdf.AccessedAugust2021.
obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/PCAST-
enterprisetomeetthechallengesofpandemicinfluenza.Availableathttps://
43. Report to the president on reengeneering the influenza vaccine production
27,33(2020).
42. Chen,J.R.etal.Betterinfluenzavaccines:anindustryperspective. J.Biomed.Sci.
Hum.VaccinImmunother. 11,1209–1222(2015).
41. Xiang, K. et al. Progress on adenovirus-vectored universal influenza vaccines.
opingthenextgenerationofinfluenzavaccines. Vaccines 8,574(2020).
40. Sayedahmed, E. E. etal.Adenoviral vector-based vaccine platforms for devel-
vaccine. PLoSONE 7,e33428–e33428(2012).
nogenicityandprotectionconferredwithanadenovirus-basedH5N1influenza
39. Pandey,A.etal.Impactofpreexistingadenovirusvectorimmunityonimmu-
8028–8038(2018).
derived virus-like particles bearing influenza hemagglutinin. Vaccine 36,
38. Won, S. Y. et al. Characterization of the innate stimulatory capacity of plant-
1491–1503(2020).
adults (>/=65 years): two multicentre, randomised phase 3 trials. Lancet 396,
rivalent, virus-like particle influenza vaccine in adults (18-64 years) and older
37. Ward,B.J.etal.Efficacy,immunogenicity,andsafetyofaplant-derived,quad-
18to49and>/=50yearsoldadults. PLoSONE 14,e0216533(2019).
likeparticleinfluenzavaccinecandidate-tworandomizedPhaseIIclinicaltrialsin
36. Pillet,S.etal.Immunogenicityandsafetyofaquadrivalentplant-derivedvirus
Immunol. 168,72–87(2016).
induces cross-reactive antibody and T cell response in healthy adults. Clin.
35. Pillet,S.etal.Aplant-derivedquadrivalentviruslikeparticleinfluenzavaccine
fightagainstCOVID-19? Vaccines 8,183(2020).
34. Rosales-Mendoza,S.etal.Whatdoesplant-basedvaccinetechnologyoffertothe
expressedin Escherichiacoli. Gene 21,273–284(1983).
33. Davis, A. R. et al. Immune response to human influenza virus hemagglutinin
bacteria. ActaBiochimPol. 61,561–572(2014).
32. Saczynska, V.Influenzavirus hemagglutinin asavaccine antigen produced in
producedin Escherichiacoli. PLoSONE 5,e11694(2010).
31. Aguilar-Yanez, J. M. et al. An influenza A/H1N1/2009 hemagglutinin vaccine
proteins. OpenForumInfect.Dis. 3,ofw015(2016).
seasonal flu vaccine comprising recombinant hemagglutinin-flagellin fusion
30. Tussey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent
ONE 3,e2257(2008).
bacterial expression: a solution to global pandemic and seasonal needs. PLoS
29. Song,L.etal.Efficaciousrecombinantinfluenzavaccinesproducedbyhighyield
1560-7917.Es.2017.22.13.30494(2017).
sibles = European communicable disease bulletin 22, https://doi.org/10.2807/
visiontoreality.Eurosurveillance:bulletinEuropeensurlesmaladiestransmis-
28. Shu,Y.&McCauley,J.GISAID:Globalinitiativeonsharingallinfluenzadata-from
167–171(2017).
effectiveness-UnitedStates,February2017. MMWRMorb.Mortal.WklyRep. 66,
27. Flannery, B. et al. Interim estimates of 2016-17 seasonal influenza vaccine
NatlAcad.Sci.USA 114,12578–12583(2017).
thataltersbindingofantibodieselicitedbyegg-adaptedvaccinestrains. Proc.
26. Zost,S.J.etal.ContemporaryH3N2influenzaviruseshaveaglycosylationsite
circulatingviruses. PLoSONE 9,e92153(2014).
with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in